Clinical Scorecard: Rheumatoid arthritis tied to birth outcomes
At a Glance
| Category | Detail |
|---|---|
| Condition | Rheumatoid Arthritis (RA) |
| Key Mechanisms | Increased rates of preterm birth and small-for-gestational-age infants associated with RA and glucocorticoid exposure. |
| Target Population | Pregnant patients with rheumatoid arthritis. |
| Care Setting | Tertiary care centers managing complex cases. |
Key Highlights
- Preterm birth rates in RA pregnancies were 16% compared to 8% in controls.
- 21% of RA pregnancies resulted in small-for-gestational-age infants versus 11% in controls.
- Moderate or high RA activity was documented in 27% of pregnancies.
- Systemic glucocorticoid exposure at doses of at least 10 mg/day was linked to nearly five times the odds of preterm birth.
- No significant differences in gestational diabetes, cesarean delivery, or congenital malformations were observed.
Guideline-Based Recommendations
Diagnosis
- Assess pregnancy outcomes in patients with rheumatoid arthritis.
Management
- Monitor disease activity and treatment exposure during pregnancy.
Monitoring & Follow-up
- Evaluate maternal characteristics and pregnancy outcomes.
Risks
- Increased odds of preterm birth and small-for-gestational-age infants in RA pregnancies.
Patient & Prescribing Data
Pregnant patients with rheumatoid arthritis enrolled in a multicenter study.
46% of pregnancies were exposed to glucocorticoids, 25% to conventional synthetic DMARDs, and 39% to biologic DMARDs.
Clinical Best Practices
- Consider the impact of RA disease activity and treatment on pregnancy outcomes.
- Evaluate the risks associated with glucocorticoid exposure during pregnancy.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
